Press Release28 Jun 2024, 11:08 pm
Dr. Reddy's and Zydus Announce Licensing Agreement for Co-Marketing of Pertuzumab Biosimilar in India
AI Summary
Dr. Reddy's Laboratories Ltd. and Zydus Lifesciences Limited have entered into a licensing agreement to co-market a Pertuzumab biosimilar, a critical treatment for HER2 positive breast cancer patients in India. The biosimilar, developed by Zydus, will be marketed under the brand names Sigrima™ by Zydus and Womab* by Dr. Reddy's. This collaboration will expand the access to this novel medicine for HER2 positive breast cancer patients in India.
Key Highlights
- Dr. Reddy's and Zydus to co-market Pertuzumab biosimilar in India for HER2 positive breast cancer patients.
- Zydus developed the biosimilar, which will be marketed under the brand names Sigrima™ and Womab*.
- This collaboration will provide comprehensive care for HER2-positive patients, offering all the three essential drugs for HER2-targeted therapy.
- Dr. Reddy's already offers biosimilar Trastuzumab (Hervycta®).
- This agreement will enable the provision of the complete standard of care to HER2 positive breast cancer patients in India.